Tags : Haemophilia A

Roche’s Hemlibra P-III Positive results for Haemophilia A without factor

Shots: The data contains HAVEN 3 (N=152) study evaluating Hemlibra (emicizumab) prophylaxis vs no prophylaxis with patients aged ≥12 yrs HAVEN 3 results: (reduction in treated bleeds 96%/qw, 97%/q2w); (zero treated bleeds 55.6%/qw, 60%q2w); (three or fewer treated bleeds 91.7%qw, 94.3%q2w); (reduction in treated target-joint bleeds 95%) The US granted Hemlibra BT&PR designations for people […]Read More